Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more
Dynavax Technologies Corporation (DVAX) - Total Assets
Latest total assets as of September 2025: $946.51 Million USD
Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) holds total assets worth $946.51 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dynavax Technologies Corporation - Total Assets Trend (2000–2024)
This chart illustrates how Dynavax Technologies Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dynavax Technologies Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Dynavax Technologies Corporation's total assets of $946.51 Million consist of 86.1% current assets and 13.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.7% |
| Accounts Receivable | $46.91 Million | 4.8% |
| Inventory | $70.05 Million | 7.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.95 Million | 0.2% |
Asset Composition Trend (2000–2024)
This chart illustrates how Dynavax Technologies Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dynavax Technologies Corporation's current assets represent 86.1% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 9.7% of total assets in 2024, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 7.1% of total assets.
Dynavax Technologies Corporation Competitors by Total Assets
Key competitors of Dynavax Technologies Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Dynavax Technologies Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Dynavax Technologies Corporation generates 0.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Dynavax Technologies Corporation generates $ 2.77 in net profit.
Dynavax Technologies Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.62 | 13.23 | 3.75 |
| Quick Ratio | 6.94 | 12.34 | 2.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $707.49 Million | $ 856.21 Million | $ 212.60 Million |
Dynavax Technologies Corporation - Advanced Valuation Insights
This section examines the relationship between Dynavax Technologies Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.30 |
| Latest Market Cap to Assets Ratio | 1.58 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | $986.26 Million |
| Market Capitalization | $1.56 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Dynavax Technologies Corporation's assets above their book value (1.58 x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Dynavax Technologies Corporation's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Dynavax Technologies Corporation (2000–2024)
The table below shows the annual total assets of Dynavax Technologies Corporation from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $986.26 Million | -1.09% |
| 2023-12-31 | $997.10 Million | +1.14% |
| 2022-12-31 | $985.85 Million | -5.14% |
| 2021-12-31 | $1.04 Billion | +194.18% |
| 2020-12-31 | $353.27 Million | +26.59% |
| 2019-12-31 | $279.07 Million | +32.33% |
| 2018-12-31 | $210.88 Million | -3.61% |
| 2017-12-31 | $218.78 Million | +99.48% |
| 2016-12-31 | $109.68 Million | -49.37% |
| 2015-12-31 | $216.63 Million | +56.65% |
| 2014-12-31 | $138.29 Million | -32.42% |
| 2013-12-31 | $204.62 Million | +46.42% |
| 2012-12-31 | $139.75 Million | +4.21% |
| 2011-12-31 | $134.10 Million | +59.17% |
| 2010-12-31 | $84.25 Million | +66.93% |
| 2009-12-31 | $50.47 Million | -44.31% |
| 2008-12-31 | $90.62 Million | -24.76% |
| 2007-12-31 | $120.45 Million | +17.07% |
| 2006-12-31 | $102.89 Million | +28.46% |
| 2005-12-31 | $80.09 Million | +8.75% |
| 2004-12-31 | $73.65 Million | +133.17% |
| 2003-12-31 | $31.59 Million | +0.34% |
| 2002-12-31 | $31.48 Million | +108.23% |
| 2001-12-31 | $15.12 Million | -48.91% |
| 2000-12-31 | $29.59 Million | -- |